viewZelira Therapeutics Ltd

Zelda Therapeutics completes enrolment for insomnia trial

The pioneering medicinal cannabis clinical trial for insomnia is treating 24 patients at the University of Western Australia sleep centre.

Zelda Therapeutics Ltd - Zelda Therapeutics completes enrolment for insomnia trial
Preliminary results are expected by February 2020

Zelda Therapeutics Ltd (ASX:ZLD) has completed the enrolment of 24 patients in Australia’s first clinical trial of medicinal cannabis to treat insomnia.

This randomised, double-blinded, placebo-controlled, cross over study will treat patients with Zelda’s proprietary insomnia formulation as well as a placebo.

The medicine for the trial has been manufactured to pharmaceutical grade GMP standards by a Europe-based speciality manufacturer.

Dosing is on-track for completion by December 2019 with preliminary results expected by February 2020.

Commercialisation planned if trial successful

Zelda’s managing director Richard Hopkins said: “This is an important milestone for the trial.

“I acknowledge the hard work and dedication from the team at the UWA sleep centre.

“Should the trial be successful, the company will move to immediately commercialise this formulation in all major global medicinal cannabis markets."

Proposed merger with US-based Ilera Therapeutics

On 9 October 2019, Zelda announced plans to merge with Ilera Therapeutics, a US-based privately held medicinal cannabis and cannabinoid science company.

Subject to approval from Zelda shareholders, and all conditions of sale being met, Zelda is proposing to acquire 100% of Ilera Therapeutics through an all-scrip transaction.

The merger will bring together a world-class portfolio of revenue-generating medicines and products undergoing clinical development that are expected to enter the market from 2020.

Hopkins added: “Zelda’s proposed merger with US-based Ilera Therapeutics will expand our access to the world’s largest cannabis markets with approximately four million registered medicinal cannabis patients.

“Zelda’s strategic partnership with European medicinal cannabis group HAPA Pharm BV also helps us access the world’s fastest growing markets outside the US.”

Quick facts: Zelira Therapeutics Ltd

Price: 0.058 AUD

Market: ASX
Market Cap: $56.05 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...



Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 21/2/20

2 min read